We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
Read MoreHide Full Article
Roche’s (RHHBY - Free Report) member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults.
As a result of the approval, Genentech has the only two FDA-approved medicines to treat AIS in its portfolio, namely TNKase and Activase (alteplase).
TNKase is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine. It is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care Activase, which is administered as an IV bolus followed by a 60-minute infusion.
The FDA approval is based on a large multi-center non-inferiority study that showed that TNKase is comparable to Activase in terms of safety and efficacy in AIS patients.
Stroke is the fifth leading cause of death. It is also the leading cause of long-term disability in the United States and affects more than 795,000 people annually.
TNKase is also FDA-approved for the treatment of acute ST-elevation myocardial infarction in adults.
Roche reported new positive data from Stage 2 and Stage 3 of the phase III OUtMATCH study on Xolair. The data provide further evidence supporting the role of Xolair (omalizumab) in treating one or more food allergies. The study is sponsored by the National Institutes of Health.
Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one or more food allergies. Stage 1 of the OUtMATCH study served as the basis for the FDA approval of Xolair for the treatment of food allergies.
In the first head-to-head trial comparing Xolair to multi-allergen oral immunotherapy (OIT), the study met its primary endpoint, showing 36% of food allergy patients treated with Xolair monotherapy could tolerate at least 2,000 mg of peanut protein and two other food allergens without experiencing an allergic reaction compared to 19% in the OIT group.
Xolair Found More Effective Than Oral Immunotherapy
Xolair was more effective with fewer side effects than OIT, which involves ingesting the food allergen, initially with a very small amount, which is then gradually increased. These findings were largely driven by the high rates of adverse events (AEs) leading to study discontinuation in the OIT-treated group.
The first 60 patients (median age: 8.5 years) from Stage 1 of the OUtMATCH study entered a 24-week open-label extension followed by Stage 3, wherein allergenic foods were introduced after treatment with Xolair.
Each of the 60 patients received a treatment plan for each of their three study allergens. Of the 180 treatment plans, 82% of initial treatment plans included dietary consumption of allergenic foods. Data observed after 12 months of follow-up showed that many patients were able to introduce allergenic foods in dietary form, although success rates were higher for milk, egg and wheat (61-70%) than for peanuts and tree nuts (38-56%).
The study found that reduced consumption of allergenic foods appeared to be related to symptoms and other factors (such as taste and aversion), with no clear predictors of dietary consumption success. Stage 3 is currently ongoing. Investigators continue to evaluate data from additional patients who completed Stage 2 and then entered Stage 3.
Roche and Novartis co-promote Xolair in the United States.
RHHBY Targets Mid-Single-Digit Growth in 2025
Roche’s performance in 2024 was good as high demand for key drugs offset the decline in sales of legacy drugs. Ophthalmology drug Vabysmo continued its stellar performance. The drug posed stiff competition to Regeneron’s (REGN) ophthalmology drug Eylea. Positive data from additional studies bode well for the drug.
Regeneron co-developed Eylea with Bayer.
Growth in hemophilia treatment Hemlibra and multiple sclerosis drug Ocrevus also boosted the top line.
The company launched two new drugs in 2024 — Itovebi for a hard-to-treat breast cancer and PiaSky for a serious blood disorder.
However, pipeline setbacks weigh on the stock. Roche also expects the loss of exclusivity for key drugs to adversely impact sales to the tune of CHF 1.2 billion in 2025.
Roche expects total sales to grow in the mid-single-digit range (at CER) in 2025. Core earnings per share are expected to grow in the high single-digit range. Roche expects to increase its dividend in Swiss francs further.
In the past 30 days, Gilead Sciences’ EPS estimate for 2025 has increased from $7.56 to $7.85. In the past 30 days, EPS estimate has increased from $7.56 to $7.85. During the same timeframe, the figure for 2026 has increased to $8.17 from $7.82.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
BioMarin Pharmaceutical
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 EPS have increased from $4.01 to $4.19. Estimate for 2026 EPS has decreased from $5.21 to $5.20 during the same timeframe. BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
Roche’s (RHHBY - Free Report) member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults.
As a result of the approval, Genentech has the only two FDA-approved medicines to treat AIS in its portfolio, namely TNKase and Activase (alteplase).
TNKase is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine. It is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care Activase, which is administered as an IV bolus followed by a 60-minute infusion.
The FDA approval is based on a large multi-center non-inferiority study that showed that TNKase is comparable to Activase in terms of safety and efficacy in AIS patients.
Stroke is the fifth leading cause of death. It is also the leading cause of long-term disability in the United States and affects more than 795,000 people annually.
TNKase is also FDA-approved for the treatment of acute ST-elevation myocardial infarction in adults.
Roche’s shares have risen 30.6% year to date compared with the large cap pharmaceutical industry’s rise of 2.1%.
Image Source: Zacks Investment Research
Results of RHHBY’s Phase III Study on Xolair
Roche reported new positive data from Stage 2 and Stage 3 of the phase III OUtMATCH study on Xolair. The data provide further evidence supporting the role of Xolair (omalizumab) in treating one or more food allergies. The study is sponsored by the National Institutes of Health.
Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one or more food allergies. Stage 1 of the OUtMATCH study served as the basis for the FDA approval of Xolair for the treatment of food allergies.
In the first head-to-head trial comparing Xolair to multi-allergen oral immunotherapy (OIT), the study met its primary endpoint, showing 36% of food allergy patients treated with Xolair monotherapy could tolerate at least 2,000 mg of peanut protein and two other food allergens without experiencing an allergic reaction compared to 19% in the OIT group.
Xolair Found More Effective Than Oral Immunotherapy
Xolair was more effective with fewer side effects than OIT, which involves ingesting the food allergen, initially with a very small amount, which is then gradually increased. These findings were largely driven by the high rates of adverse events (AEs) leading to study discontinuation in the OIT-treated group.
The first 60 patients (median age: 8.5 years) from Stage 1 of the OUtMATCH study entered a 24-week open-label extension followed by Stage 3, wherein allergenic foods were introduced after treatment with Xolair.
Each of the 60 patients received a treatment plan for each of their three study allergens. Of the 180 treatment plans, 82% of initial treatment plans included dietary consumption of allergenic foods. Data observed after 12 months of follow-up showed that many patients were able to introduce allergenic foods in dietary form, although success rates were higher for milk, egg and wheat (61-70%) than for peanuts and tree nuts (38-56%).
The study found that reduced consumption of allergenic foods appeared to be related to symptoms and other factors (such as taste and aversion), with no clear predictors of dietary consumption success. Stage 3 is currently ongoing. Investigators continue to evaluate data from additional patients who completed Stage 2 and then entered Stage 3.
Roche and Novartis co-promote Xolair in the United States.
RHHBY Targets Mid-Single-Digit Growth in 2025
Roche’s performance in 2024 was good as high demand for key drugs offset the decline in sales of legacy drugs. Ophthalmology drug Vabysmo continued its stellar performance. The drug posed stiff competition to Regeneron’s (REGN) ophthalmology drug Eylea. Positive data from additional studies bode well for the drug.
Regeneron co-developed Eylea with Bayer.
Growth in hemophilia treatment Hemlibra and multiple sclerosis drug Ocrevus also boosted the top line.
The company launched two new drugs in 2024 — Itovebi for a hard-to-treat breast cancer and PiaSky for a serious blood disorder.
However, pipeline setbacks weigh on the stock. Roche also expects the loss of exclusivity for key drugs to adversely impact sales to the tune of CHF 1.2 billion in 2025.
Roche expects total sales to grow in the mid-single-digit range (at CER) in 2025. Core earnings per share are expected to grow in the high single-digit range. Roche expects to increase its dividend in Swiss francs further.
RHHBY’s Zacks Rank and Other Stocks to Consider
Roche currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are Gilead Sciences (GILD - Free Report) and BioMarin Pharmaceutical (BMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Gilead Sciences
In the past 30 days, Gilead Sciences’ EPS estimate for 2025 has increased from $7.56 to $7.85. In the past 30 days, EPS estimate has increased from $7.56 to $7.85. During the same timeframe, the figure for 2026 has increased to $8.17 from $7.82.
GILD’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.47%.
BioMarin Pharmaceutical
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 EPS have increased from $4.01 to $4.19. Estimate for 2026 EPS has decreased from $5.21 to $5.20 during the same timeframe. BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.